Searched for
INDIAN BIOTECH COMPANIES
Startup seed rounds double as VCs turn more selectiveIndian startups are securing significantly larger seed and early-stage funding rounds, nearly doubling their average cheque size. This tren...- From Rs 4,900 crore to Rs 41,300 crore: How Sanjeev Bikhchandani turned 135 startups into a 743% return machineSanjeev Bikhchandani's Info Edge has achieved remarkable capital compounding, deploying Rs 4,900 crore across 135 startups since 2007, now ...
- When frontier AI can be switched off: India's sovereignty challengeIndia must not depend on foreign AI models, as US export controls demonstrate potential access denial. Past reliance on external tech, like...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities ended higher on Tuesday, supported by easing geopolitical tensions and softer crude prices. A sharp drop in India VIX boost...
- Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, othersThe Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- H-1B chill sets in; Flipkart doubles down on ShopsyUS demand for H-1B visas has slumped to a seven-year low amid steeper costs and Trump-era policy shifts. This and more in today’s ETtech To...
- Flipkart puts IPO on ice; Rapido's $240 million raiseFlipkart has hit pause on its IPO in a jittery market. This and more in today's ETtech Top 5.
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- 'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...
- Deeptech bets heat up; Paytm, PB Fintech, Meesho earningsHappy Thursday! VCs are doubling down on India’s deeptech, with early-stage bets leading the charge. This and more in today’s ETtech Mornin...
- Early-stage tech draws VC interest across aviation, biotech, precision manufacturingInvestors are prioritising smaller, early-stage deals in deeptech sectors like AI, healthcare, and precision manufacturing, shying away fro...
- Vivek Ramaswamy wins Republican nomination for Ohio governor after Trump's endorsementOhio voters have chosen their candidates for key November elections. Billionaire Vivek Ramaswamy will face Dr. Amy Acton for governor. Sena...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
Load More
